Gilead halts leukaemia study on positive results PMLiVE The trial - known as Study 116 - is comparing idelalisib plus Roche/Biogen Idec's Rituxan (rituximab) to rituximab alone in patients unsuitable for treatment with conventional chemotherapy. At an interim analysis, the combination was found to have a ... Gilead Stops Cancer Drug Trial Early On Positive Results UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic ... Gilead stops leukaemia drug trial early |
